March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Lucentis in Advanced MAcular degeneration (LAMA) Trial - Visual Function Questionnaire (VFQ) Results
Author Affiliations & Notes
  • Steven R. Sanislo
    Ophthalmology, Eye Inst at Stanford - Stanford Univ, Palo Alto, California
  • Anne E. Fung
    Ophthalmology, California Pacific Medical Center, San Francisco, California
  • Michael J. Jumper
    West Coast Retina Medical Group, San Francisco, California
  • Manfred MacKeben
    Smith-Kettlewell Eye Res Inst, San Francisco, California
  • Donald C. Fletcher
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    Smith-Kettlewell Eye Res Inst, San Francisco, California
  • Footnotes
    Commercial Relationships  Steven R. Sanislo, Genentech (F), Oraya Theraputics (C); Anne E. Fung, Genentech (F); Michael J. Jumper, None; Manfred MacKeben, None; Donald C. Fletcher, None
  • Footnotes
    Support  Research sponsored by Genentech
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4396. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven R. Sanislo, Anne E. Fung, Michael J. Jumper, Manfred MacKeben, Donald C. Fletcher; Lucentis in Advanced MAcular degeneration (LAMA) Trial - Visual Function Questionnaire (VFQ) Results. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4396.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate changes in VFQ-25 questionnaire scores after treatment for a cohort of patients with advanced active exudative AMD.

Methods: : 18 patients with advanced exudative AMD and visual acuity 20/400 or worse were treated with ranibizumab monthly for 3 or 6 months and then as needed. VFQ-25 questionnaires were completed at baseline and at 3, 6, and 12 months.

Results: : Composite scores: For the group containing all patients, mean VFQ score at baseline was 58 points. This did not change at 3 or 6 months. At 12 months, mean VFQ score was 6 points below baseline. When the study eye was the better seeing eye at baseline, VFQ score at baseline was 30 points. This was improved by 16 points at 3 months and was 6 points above baseline at 6 months. 12 months results are not yet available.Sub-group scores: For the group containing all patients General vision sub-score improved by 5 points at 3 months and 7 points at 6 months, but returned to baseline at 12 months. Near activity sub-score was unchanged at 3 and 6 months but was 15 points below baseline at 12 months. Distance activity sub-score reduced by 7 points at 3 months, returned to baseline at 6 months and was 10 points below baseline at 12 months. Driving sub-score reduced by 5 points at 3 months, was 3 points below baseline at 6 months, and was 13 points below baseline at 12 months. Color vision sub-score was unchanged at all time-points. Peripheral vision sub-score reduced by 5 points at 3 months, 6 points at 6 months, and 11 points below baseline at 12 months. When the study eye was the better seeing eye, sub-score results generally showed far more improvement from baseline than for the group that included all patients.

Conclusions: : Overall, VFQ-25 scores did not show significant improvement with treatment. However, in the case where the study eye was the better seeing eye VFQ-25 scores showed significant improvement with treatment. These results may support treatment in cases of very advanced exudative AMD where the treatment eye is the better seeing eye. But these results might not support treatment in cases where the fellow eye has significantly better vision. In order to best assess the potential benefits of treatment of advanced AMD, other measurements of visual function must also be taken into account.

Clinical Trial: : http://www.clinicaltrials.gov NCT00896779

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×